TREATMENT OF BURKITT'S AND UNDIFFERENTIATED NON-BURKITT'S LYMPHOMA USING INTENSIFICATION HIGH-DOSE ARA-C AND EXTENDED CONSOLIDATION CHEMOTHERAPY. AN ECOG STUDY (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

TREATMENT OF BURKITT'S AND UNDIFFERENTIATED NON-BURKITT'S LYMPHOMA USING INTENSIFICATION HIGH-DOSE ARA-C AND EXTENDED CONSOLIDATION CHEMOTHERAPY. AN ECOG STUDY (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 9:A1010 1990. Unique Identifier : AIDSLINE ICDB/90661789
Mazza JJ; Hines JD; Anderson JW; O'Connell MJ; Marshfield Clinic, Marshfield, WI 54449

Abstract: 73 patients (pts) were entered into a protocol for treatment of Burkitt's and undifferentiated non-Burkitt's lymphoma (EST3484) consisting of induction chemotherapy (CTX 1.2 g/m2 day 1; Oncovin 1.4 mg/m2 days 3, 10, 17 and 24; MTX 300 mg/m2 iv day 12 followed by leucovorin rescue; prednisone 60 mg/m2 po days 3-30 with tapering dose schedule days 30-37) (COMP) and intrathecal MTX 6.25 mg/m2 days 5, 31 and 34. CRs and PRs were given 1 course of intensification therapy (CTX 1.0 g/m2 iv and Ara-C 3 g/m2 iv q 12 hr x 6 doses) after marrow recovery. Consolidation therapy consisted of alternating cycles of Ara-C (3 g/m2 iv q 12 hr x 6 doses) and COMP (CTX 1.0 g/m2 iv day 1; Oncovin 1.4 mg/m2 iv day 1; MTX 300 mg/m2 iv day 15 followed by leucovorin rescue; prednisone 60 mg/m2 po days 1-5 and IT-MTX 6.25 mg/m2 on day 1 followed by leucovorin rescue). Four cycles of each consolidated regimen were given. Eighteen pts were excluded in pathology review, 2 pts were ineligible because of a diagnosis of AIDS or ARC and 3 other pts were excluded because of protocol violations. Thus, 50 pts were analyzed for response. Six of these pts were entered with no evidence of disease after surgery and were unevaluable for response. There were 14 CRs and 14 PRs after induction chemotherapy. Three of the PRs achieved a CR after intensification resulting in 17 CRs and a CR rate of 38% (17/44). The overall response rate to induction therapy was 64% (28/44). There were 2 toxicity-related deaths during induction therapy in the 50 analyzable pts, both due to sepsis. Only 3 pts, thus far, have relapsed.

Keywords: Antineoplastic Agents, Combined/*THERAPEUTIC USE Burkitt's Lymphoma/*DRUG THERAPY Clinical Trials Combined Modality Therapy Comparative Study Cytarabine/*ADMINISTRATION & DOSAGE Dose-Response Relationship, Drug Drug Administration Schedule Human Lymphoma, Non-Hodgkin's/*DRUG THERAPY CLINICAL TRIAL ABSTRACT
900930
M9094778

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .